Tag Archives: A1C

A1C is one of the most useful tools in diabetes care, but it has an important limitation: it takes time to reflect change. Could a faster-moving marker help clinicians know sooner whether treatment is working? New randomized research on glycated albumin in diabetes offers an intriguing answer. Glycated albumin reflects …

Medical nutrition therapy for diabetes is often discussed in terms of A1C, glucose levels, and weight. However, could personalized nutrition also influence inflammation and other aspects of metabolic health? A recent randomized controlled trial offers an intriguing reason to ask that question. Researchers found that individualized medical nutrition therapy with …

For decades, A1C has served as the gold standard for assessing long-term glucose control in people with diabetes. However, it tells only part of the story. Researchers are now exploring whether metabolic flexibility could become an important biomarker in diabetes, offering a deeper understanding of metabolic health than A1C alone. …

For decades, A1C has served as the cornerstone of diabetes management. It remains an essential marker because it reflects average blood glucose levels over approximately three months. However, many clinicians are recognizing that managing post-meal glucose levels may provide equally important insights into a patient’s metabolic health. A person can …

Managing post-meal glucose levels plays a critical role in diabetes care, yet it is often overlooked in favor of A1C and time in range. However, what happens after meals can significantly affect long-term outcomes. Think of it like traffic flow: even if the highway looks clear overall, sudden congestion at …

As GLP-1 therapies become a long-term cornerstone in diabetes care, monitoring patients on these treatments is gaining renewed attention. Clinicians once focused mainly on A1C and weight, but is that enough today? Much like checking only the speed of a car without looking at fuel or engine health, relying on …

Nonalcoholic steatohepatitis (NASH) and metabolic dysfunction–associated steatotic liver disease (MASLD) are rapidly becoming leading causes of chronic liver disease worldwide. Traditionally, clinicians have associated MASLD with obesity, insulin resistance, and type 2 diabetes, often using body mass index (BMI) and A1C as screening triggers. However, an important shift is occurring …

For decades, clinicians have relied on A1C as the primary benchmark for diabetes control. Yet many patients and providers now wonder: does a single quarterly number truly reflect daily glucose fluctuations and risks? As continuous glucose monitoring (CGM) becomes more accessible, the metric known as Time in Range (TIR) has …